Showing results (221-230 of 253) with videos related to

Sort By:
Pageof 26
Journal of the American Society of Nephrology : JASN|April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyDick de Zeeuw, Blai Coll, Dennis Andress, et al.
Journal of the American Heart Association|September 23, 2020
NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes MellitusMarcus V B Malachias, Pardeep S Jhund, Brian L Claggett, et al.
Diabetes, Obesity & Metabolism|December 27, 2016
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathyMichelle J Pena, Dick de Zeeuw, Dennis Andress, et al.
Immunologic Research|June 21, 2015
Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral lociBjørn A Nexø, Palle Villesen, Kari K Nissen, et al.
Journal of Hypertension|March 14, 2007
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studiesWouter B A Eijkelkamp, Zhongxin Zhang, Barry M Brenner, et al.
European Journal of Preventive Cardiology|August 1, 2015
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markersBauke Schievink, Dick de Zeeuw, Paul A Smink, et al.
Clinical Chemistry|September 20, 2011
Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetesClaudia Cangemi, Vibe Skov, Michael Kjaer Poulsen, et al.
Pageof 26